DUB

WP1130 (Degrasyn) is a novel selective small molecular deubiquitinase inhibitor and a Bcr/Abl destruction pathway activator that specifically and rapidly down-regulates both wild-type and mutant Bcr/Abl protein without affecting bcr/abl gene expression in chronic myelogenous leukemia (CML) cells.

NSC632839 is a nonselective isopeptidase inhibitor, which inhibits USP2, USP7, and SENP2 with EC50s of 45??4 μM, 37??1 μM, and 9.8??1.8 μM, respectively.

LDN-57444 is a potent, reversible, competitive and active site-directed inhibitor of UCHL1.

P 22077 is a cell-permeable inhibitor of the ubiquitin-specific protease (IC?? = 8.6 μM) and the closely related deubiquitinase (DUB) USP47.

PR-619 is a cell-permeable, reversible, and broad-spectrum inhibitor of the deubiquitinylating enzymes (DUBs).

IU1 is a selective inhibitor of Usp14. It inhibits the catalytic activity of proteasome-associated Usp14 in vitro (IC50 < 4 uM).

P005091 is a selective inhibitor of ubiquitin-specific protease (USP) 7 (IC50 = 4.2 uM).

ML323 is a selective and highly potent USP1-UAF1 inhibitor links deubiquitination to DNA damage responses.

NSC 687852 is an inhibitor of ubiquitin-specific-processing protease 14 (USP14) and ubiquitin carboxyl-terminal hydrolase isozyme L5 (UCHL5), two proteasome-associated DUBs.

ML364 is a selective ubiquitin specific peptidase 2 (USP2) inhibitor (IC50=1.1 μM) with anti-proliferative activity.

C527 is a is a pan DUB enzyme inhibitor, with a high potency for the USP1/UAF1 complex (IC50=0.88 μM).

RA-9 is a potent and selective proteasome-associated deubiquitinating enzymes (DUBs) inhibitor with favorable toxicity profile and anticancer activity.